Lavipharm

Lavipharm Debt/EBITDA

The Total Debt to EBITDA Ratio of Lavipharm (LAVI.AT) as of Nov 4, 2026 is 3.96. In the previous year, Total Debt to EBITDA Ratio was 6.04 — a change of -34.36% (lower).

Debt/EBITDA

3.96

YoY

-34.36%

Last updated:

Total Debt to EBITDA Ratio of Lavipharm is 2025 3.96 . Total Debt to EBITDA Ratio of Lavipharm was 2024 6.04 . It decreases by -34.36% lower compared to the previous year.

The Lavipharm Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
92.99 EUR
Jan 1, 2019
21.75 EUR
Jan 1, 2020
11.77 EUR
Jan 1, 2021
46.78 EUR
Jan 1, 2022
13.78 EUR
Jan 1, 2023
6.18 EUR
Jan 1, 2024
6.04 EUR
Jan 1, 2025
3.96 EUR
The Lavipharm Debt/EBITDA history
YEARDebt/EBITDAYoY
3.96-34.36%
6.04-2.38%
6.18-55.13%
13.78-70.54%
46.78+297.46%
11.77-45.88%
21.75-76.61%
92.99+576.55%
13.74-92.39%
180.51+377.22%
37.83-653.73%
-6.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lavipharm stock

Total Debt to EBITDA Ratio of Lavipharm is 3.96 in 2025.

Total Debt to EBITDA Ratio of Lavipharm changed from 6.04 to 3.96, representing a -34.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Lavipharm since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Lavipharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Lavipharm

All Key Metrics — Lavipharm